Macquarie Group’s Tempest Therapeutics TPST Stock Holding History

Macquarie Group’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2	Closed	-$8K	–	2358
2017 Q4	$8K	Buy	+2	New	+$8.39K	﹤0.01%	2312

Other funds holding TPST

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Macquarie Group's TPST Position: Q1 2018 in Review

Macquarie Group sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 2 shares — an estimated $8K sold.

Macquarie Group first reported a position in TPST in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

Macquarie Group reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 2 Tempest Therapeutics shares in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Tempest Therapeutics in Q4 2017 and held it in 1 quarter.
Macquarie Group's Tempest Therapeutics position peaked at $8K in Q4 2017.
41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.